Biochem/physiol Actions

Moclobemide acts as a substrate for cytochrome P450 2C19 (CYP2C19). It also behaves as an inhibitor of cytochrome P450 2D6 (CYP2D6), cytochrome P450 1A2 (CYP1A2 and CYP2C19. Moclobemide is also involved in the increased expression of B-cell lymphoma 2 (BcL-2). It also causes neural stem cell (NSC) differentiation into serotoninergic neuron by extracellular‐regulated kinase (ERK) pathway.

Moclobemide is a reversible monoamine oxidase A inhibitor (MAOI); antidepressant. Elimination half-life in humans = 1 -3 hrs; absolute oral bioavailability. Unlike other MAO inhibitors, does not significantly increase blood pressure in humans upon combination with tyramine.

Features and Benefits

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is featured on the Dopamine and Norepinephrine Metabolism page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Other Notes

Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. M3071.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

Packaging

10, 50 mg in glass bottle